Prostate specific antigen (PSA) value adjusted for transition zone volume and free PSA (y-seminoprotein)/PSA ratio in the diagnosis of prostate cancer in patients with intermediate PSA levels

British Journal of Urology

Volumn 82, Issue 2, 1998, Pages 224-230

  Kurita, Y ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA SEMINOPROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOPSY; CANCER DIAGNOSIS; CLINICAL TRIAL; DEVICE; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOASSAY; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; TRANSRECTAL ULTRASONOGRAPHY;

AGED; AGED, 80 AND OVER; BIOPSY; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0031822861     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Catalona WJ. Smith DS. Ratliff TL, Basler JVV. Detection of organ-confined prostate cancer is increased through prostate-specific antigen based screening. JAMA 1993: 270: 948-54
2. Catalona WJ, Richie JP. Ahmann FR el al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J L'rol 1994; 151: 1283-90
3. Benson MC. Whang IS. Olsson CA. McMahon DJ. Looner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J U ml 1992; 147: 817-21
4. Lepor H. Wang B. Shapiro E. Relationship between prostatic epithelial volume and serum prostate-specific antigen levels. Urology 1994: 44: 199-205
5. McNeal ]. Pathology of benign prostatic hyperplasia. Insight into etiology. Ural Clin North Am 1990: 17: 477-86
6. Kalish J. Cooner WH. Graham SD Jr. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 1994: 43: 601-6
7. Kurita Y. Ushiyama T. Suzuki K. Fujita K. Kavvabe K. PSA value adjusted for transition zone volume in the diagnosis of prostate cancer. lut J Vml 1996: 3: 367-72
8. Zlotta AR, Djavan B. Marberger M, Schulman C. Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol 1997: 157: 1 315-21
9. Christensson A, Björk T. Nilsson O et til. Serum prostate specific antigen complexée! to al-antichymotrypsin as an indicator of prostate cancer. J Urol 1993: 150: 100-5
10. Catalona WJ, Smith DS. Wolf'ert RL el al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995: 274: 1214-20
11. Bangma CH. Rietbergen J. Bw Kranse R. Blijenberg B(l, Petterson K. Schröder FH. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol 1997; 157: 2191-6
12. Stephan C, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 1997; 79: 104-9
13. Schaller J, Akiyama K, Tsuda R. Hara M, Marti T. Rickle E. Isolation, characterization and amino-acid sequence of y-seminoprotein from human seminal plasma. EurJ Biochem 1987; 170: 111-20
14. Lundwall A, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEES Lett 1987; 214: 317-22
15. Kawakami K, Tsukada T, Nakayama T. Analysis on inhibitory reaction of y-Sm, a marker for prostate cancer. ]pn }Clin Pathol 1992: 40: 245
16. Demura T, Shinohara N. Tanaka M et al The proportion of free to total prostate specific antigen. Cancer 1996: 77: 1137-43
17. Demura T, Watarai Y, Togashi M, Hirano T, Ohashi N, Koyanagi T. Measurement of prostate specific antigen/ gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer. J Urol 1993; 150: 1740-5
18. Metz CE. Some practical issues of experimental design and data analysis in radiological ROC studies. Invest Radio! 1989; 24: 234-45
19. Hanley JA, McNeil BJ. The meaning and use of area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36
20. Stamey TA. Yang N. Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Eng }Med 1987: 317: 909-16
21. Weber JP, Oesterling JE, Peters CA, Partin AW, Chan DW. Walsh PC. The influence of reversible antigen deprivation serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J Urol 1989; 141: 987-92
22. Bazinet M, Meshref AW. Trudel C et al. Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 1994; 43: 44-52
23. Ramon J, Boccon-Gibod L, Billebaud T et al Prostatespecific antigen density: a means to enhance detection of prostate cancer. Eur Urol 1994; 25: 288-94
24. Hammerer PG, McNeal JE. Stamey TA. Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J Urol 1995; 153: 111-4
25. Kuriyama M. Akimoto S, Akaza H et al. Comparison of various assay system for prostate-specific antigen standardization. Jpn J Clin Oncol 1992; 22: 393-9